Impact of solid / vapour equilibria on conditions of crystallization of pharmaceutical compounds

Abstract

The influence of solvent (in its gaseous state) on the stability of crystallized organic compounds was investigated. Through two examples of studies on the solid/vapour equilibria made in our lab, several behaviors were highlighted: (i) a new hydrated phase (thermodynamically stable) of an active pharmaceutical ingredient (API) was detected after the recrystallization starting from a deliquescent state, (ii) a spontaneous resolution of a hydrated racemic compound towards an anhydrous conglomerate can occur during the desolvation under the precise conditions of temperature and humidity. This study illustrates that knowledge about solid/vapour equilibrium is a crucial step during the complete characterization of solid organic compounds.

Keywords

solid/vapour equilibria / hydrates / deliquescence / pharmaceutical solids / dynamic vapour sorption

References

[1] Authelin J. R.. Thermodynamics of non-stoichiometric pharmaceutical hydrates[J]. International Journal of Pharmaceutics, 2005, 303(1/2): 37-53.

[2] Henck J. O., Griesser U. J., Burger A.. Polymorphism of drug substances: An economic challenge[J]. Pharm Ind, 1997, 59(2): 165-169.

[3] Khanhari R., Chen L., Grant D. J. W.. Physical characterization of nedocromil sodium hydrates[J]. J Pharm Sci, 1998, 87(9): 1052-1061.

[4] Petit S., Coquerel G.. Mechanism of several solid-solid transformations between dihydrated and anhydrous copper (II) 8-hydroxyquinolinates. Proposition for a unified model for the dehydration of molecular crystals[J]. Chem Mater, 1996, 8(9): 2247-2258.

[5] Chan M. N., Kreidenweis S. M., Chan C. K.. Measurements of hygroscopic and deliquescence properties of organic compounds of different solubilities in water and their relationship with cloud condensation nuclei activities [J]. Env Sci Tech, 2008, 42(10): 3602-3608.

[6] Coquerel G, Sanselme M, Lafontaine A. Method of Measuring Scattering of X-rays, Its Applications and Implementation Device: WO, 136921. A1 [P]. 2011-04-06 (in French).

[7] Descamps G.. Purification by Crystallization of a New Organic Phosphored Active Pharmaceutical Ingredient [D]. 2009, Rouen: University of Rouen.

[8] Amharar Y., Petit S., Sanselme M., et al. Crystal structures, dehydration mechanism and chiral discrimination in the solid state of hydantoin derivatives [J]. Cryst Growth Des, 2011, 11(6): 2453-2462.

[9] Descamps G, Amharar Y, Cartigny Y et al. Novel Polymorphic Form of CHDMAPP, Method of Preparation Thereof, and Pharmaceutical Composition Comprising Same: WO, 029062.A1 [P]. 2010-03-18.

[10] Newman W., Reutzel-Edens S. M., Zografi G.. Characterization of the “hygroscopic” properties of an active pharmaceutical ingredient[J]. J Pharm Sci, 2008, 97(3): 1047-1059.

[11] Sakai K., Hirayama N., Tamura R.. Topics in Current Chemistry (Novel Optical Resolution Technologies)[M]. 2007, Springer: Berlin Heidelberg 1-50.

[12] Courvoisier L., Ndzié E., Petit M.-N., et al. Influence of the process on the mechanisms and the performances of the preferential crystallization: Example with (±)-5-(4-bromophenyl)-5-methylhydantoin[J]. Chem Letter, 2001, 30(4): 364-365.

[13] Belokon Y.. (S)-2-[N-(N′-benzylprolyl) amino] benzophenone (BPB): A reagent for the synthesis of optically pure α-amino acids [J]. Janssen Chimica Acta, 1992, 10(2): 4-12.

[14] Tauvel G, Cartigny Y, Sanselme M et al. Study of solidliquid and solid-vapor equilibria in tenatoprazole potassium salt/solvents systems [C]. In: 37th Conference on Phase Equilibria Proceedings. EDP Sciences, 2011.

[15] Couvrat N, Cartigny Y, Coquerel G. Influence of solid/vapour equilibria on the stability of organic solids [J]. In: 35th Conference on Phase Equilibria Proceedings. EDP Sciences, 2009.

[16] Descamps G., Cartigny Y., Sanselme M., et al. Structural and physico-chemical characterization of a solid solution produced by antisolvent crystallization of a new phosphoantigen [J]. Crystal Growth Des, 2009, 9(9): 3910-3917.

[17] Balavoine F, Madec J, Schneider J-M et al. Method for the Preparation of (3S,3S′) 4,4′-Disulfanediylbis(3-Aminobutane 1-sulfonic acid): WO, 045849[P]. 2012-04-12.